A205470 Stock Overview
Humasis Co. Ltd. manufactures and sells pharmaceuticals and medical devices in South Korea and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 1/6 |
Rewards
Risk Analysis
Humasis Co. Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₩1,768.00 |
| 52 Week High | ₩3,470.00 |
| 52 Week Low | ₩1,622.00 |
| Beta | -0.88 |
| 1 Month Change | -12.04% |
| 3 Month Change | -0.62% |
| 1 Year Change | -43.51% |
| 3 Year Change | -74.10% |
| 5 Year Change | 292.89% |
| Change since IPO | 271.23% |
Recent News & Updates
Shareholder Returns
| A205470 | KR Medical Equipment | KR Market | |
|---|---|---|---|
| 7D | -1.7% | 7.6% | 3.4% |
| 1Y | -43.5% | 33.4% | 7.1% |
Price Volatility
| A205470 volatility | |
|---|---|
| A205470 Average Weekly Movement | 7.0% |
| Medical Equipment Industry Average Movement | 6.3% |
| Market Average Movement | 5.2% |
| 10% most volatile stocks in KR Market | 11.8% |
| 10% least volatile stocks in KR Market | 2.4% |
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2000 | 231 | Sung-gon Kim | www.humasis.com |
Humasis Co. Ltd. manufactures and sells pharmaceuticals and medical devices in South Korea and internationally. It offers immunodiagnostic kits, such as quantitative and qualitative tests, cardiac and cancer markers, infectious diseases, hormones, and women’s health. The company also provides bio-material products, such as COVID-19 nucleocapsid protein, human immunodeficiency virus surface proteins, COVID-19 RT-PCR kit, and COVID-19 Variant RT-qPCR kit, as well as MPXV real time PCR kit, a real-time polymerase chain reaction assay for the qualitative detection of nucleic acid from Monkeypox virus.
Humasis Co. Ltd. Fundamentals Summary
| A205470 fundamental statistics | |
|---|---|
| Market cap | ₩224.91b |
| Earnings (TTM) | -₩55.42b |
| Revenue (TTM) | ₩13.83b |
16.3x
P/S Ratio-4.1x
P/E RatioIs A205470 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| A205470 income statement (TTM) | |
|---|---|
| Revenue | ₩13.83b |
| Cost of Revenue | ₩50.82b |
| Gross Profit | -₩36.99b |
| Other Expenses | ₩18.43b |
| Earnings | -₩55.42b |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -435.68 |
| Gross Margin | -267.55% |
| Net Profit Margin | -400.83% |
| Debt/Equity Ratio | 0% |
How did A205470 perform over the long term?
See historical performance and comparison